Introduction

vet06701

Company name: Janssen Animal Health

A division of Janssen-Cilag Ltd

50-100 Holmers Farm Way

High Wycombe

Buckinghamshire

HP12 4EG

Telephone: 01494 567555

Fax: 01494 567556

Email: ahealth@jacgb.jnj.com

Presentation

Clear, colourless to pale yellow sterile aqueous solution of polysulphated glycosaminoglycan. 100 mg PSGAG per ml in 5 ml vials for intramuscular injection.

Uses

For the treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital flexor tendonitis.

Dosage and administration

The contents of a 5 ml ampoule (100 mg/ml) are injected by deep intra-muscular injection every four days for a total of seven injections.

Contraindications, warnings, etc

If signs or symptoms of hypersensitivity occur, the treatment must be discontinued.

Do not use in pregnant animals.

Treatment should not be given in cases of advanced renal or hepatic diseases.

The product may potentiate the action of other anticoagulant preparations.

In the absence of compatibility studies, do not mix with other drugs.

For animal treatment only. Keep out of reach of children.

Withdrawal period

0 (zero) days

Overdose

In the case of overdosage, blood coagulation time as measured by activated partial thromboplastin time might be prolonged for a few hours after the injection.

Pharmaceutical precautions

Do not store above 25 °C. Protect from light.

Legal category

POM-V

Packaging Quantities

Carton with 7 ampoules, 5 ml each, for intra-muscular injection.

Further information

In traumatic and degenerative joint disease the natural balance between synthesis and degradation of cartilage shifts towards increasing degradation resulting in loss of mucopolysaccharides. Adequan is chemically similar to the mucopolysaccharides of cartilage and is concentrated in cartilaginous tissue. Adequan has been shown to be an inhibitor of cartilage degrading enzymes and to stimulate the metabolism of chondrocytes and synovial cells. Adequan inhibits the development and progression of degenerative joint diseases.